Biologics Redefine Clear in Psoriasis
Nearly one dozen therapies have reached the psoriasis market, and the new standard is at least 90% skin clearance—an achievement previously unmet.
Related Articles
Female Sex, Recent Pregnancy Linked to Poor HCV Treatment Rates in Opioid Use Disorder
Female sex and recent pregnancy were independent risk factors for reduced likelihood of DAA prescription among people with HCV entering opioid use disorder treatment.
Female Sex, Recent Pregnancy Linked to Poor HCV Treatment Rates in Opioid Use Disorder
Female sex and recent pregnancy were independent risk factors for reduced likelihood of DAA prescription among people with HCV entering opioid use disorder treatment.
Study Highlights Complex Role of IL-13 Among Patients with Bullous Pemphigoid
This analysis suggests serum IL-13 levels are lower in bullous pemphigoid patients than in healthy controls and pemphigus vulgaris patients.
How Family History Distinguishes Bipolar Depression From MDD, With Jerry McGuire, MD
At 2025 So Cal Psych, McGuire shared insights on diagnosing bipolar depression, treating agitation in dementia, and managing mental health challenges in patients who stutter.
Making the Switch in Atopic Dermatitis: Optimizing Treatment Targets With JAK Inhibitors
Christopher Bunick, MD, PhD, and Lindsay Ackerman, MD, FAAD, discuss how Janus kinase (JAK) inhibitors are revolutionizing atopic dermatitis treatment by providing faster, deeper, and…
Hypercortisolism in Patients with Treatment-Resistant Type 2 Diabetes, with Richard Auchus, MD, PhD
Auchus discusses his recent presentation on the CATALYST trial, investigating the characteristics of patients with difficult-to-treat T2D because of hypercortisolism.
Concurrent Lifestyle Intervention Enhances Semaglutide Weight Loss, with Qiaochu Xue, PhD, MPH
Lifestyle intervention yielded greater maintained weight loss 12 months after discontinuing semaglutide than without.
Liver Lineup: Progress, Policy, and Barriers in Hepatitis C Elimination
Hosts Kimberly Brown and Nancy Reau discuss policy, clinical, and structural milestones enabling HCV elimination efforts and critical gaps impeding progress.
Brief CBT Eases Food Allergy Anxiety, With Marcus Shaker, MD
Shaker shares how allergist-immunologists can use brief CBT, motivational interviewing, and risk reframing to shift patients’ fear of their food allergies into confidence.
FDA Issues CRL to Deramiocel for Treating Cardiomyopathy Secondary to DMD
Capricor Therapeutics intends to resubmit a BLA for the potential first-in-class treatment with topline data from the ongoing HOPE-3 trial in Q3 2025.